Fingolimod S1P Receptor inhibitor analysis of PFS was the only statistically significant

Treated even in the PFS for cetuximab was observed, with median progression-free survival of 9.2 months versus 7.8, although this was not statistically significant. The independent Independent assessment of progression-free survival in patients with mutations Fingolimod S1P Receptor inhibitor in codons 12 and 13 showed no difference. In the subgroup analysis of PFS was the only statistically significant differences in patients with KRAS mutations are observed, which favors treatment with cetuximab in patients with rectal cancer, a metastatic site, or Eastern Cooperative Oncology Group performance status 0 OS. In the ITT population was for OS Arm A, B and C are almost identical. In patients with KRAS wild-type KRAS / BRAF wild-type double, andKRASmutant tumors, there was no difference between the OS curves for the three treatment groups.
No significant effect of cetuximab on OS was found in any of the subgroups analyzed. Factor Xa activity R0 resection rate. In the ITT population, the incidence of metastases R0resection was8% with8 inarmA%, 11% in arm B, and 5% in arm C. The figures for the populations of the KRAS gene are also listed in Table 2. The patients were again U is a median of two cycles CAPEOX. Among the 84 patients from CAPEOX, were 79 patients with CRT and 77 patients ran the operation. The median time between the end of RT, the operation was 6.8 weeks. Among the patients who TME R0 resection surgery was performed in 72 patients and 86% on an ITT basis. Table 2 shows the comparison between the anf Nglichen rate of pathologic evaluation and postoperative MRI. PCR was observed in 19 of 77 patients and 19 of the 84 patients on an ITT.
Initially seven patients with MRI-defined tumor defined T4 and T3 tumors, 12 patients with MRI Highest obtain a PCR. Fifteen of these patients had positive nodes at the base. T stage was reduced in 53 patients and non Changed in 23 patients. Only one patient with stage T3 MRI has progressed to a stage pT4. This patient had peritoneal carcinomatosis at the time of surgery. Two other patients had liver metastases of a total number of patients with metastatic disease, three, or a failure rate can pr Be operative CT diagnosis 4%. In Table 3, 3 and 4 degrees of toxic effects at induction chemotherapy and chemoradiotherapy are listed. Four patients died may need during the induction chemotherapy. He had colitis, leading to a sepsis.
The second patient developed acute renal failure, Bilateral bronchopneumonia and pulmonary embolism several Minderj Hrige completed as described in the autopsy report. The third died of ileus and the autopsy report also showed signs of heart failure. The fourth patient died from subject to debate Words cause, after two rounds of CAPEOX. An autopsy was performed. Two F ll Of stroke were observed after treatment CAPEOX-and medium-term CRT. One patient had a resectable tumor after completion of induction chemotherapy to chemoradiotherapy and both, but was considered unsuitable for surgery. Morbidity t were within 30 days after surgery, fistula formation, anastomotic leak, pelvic abscess and local infection. Two weeks after surgery, the patient aspirated contrast medium from an R Ntgenuntersuchung and cardiac arrest. Two weeks after surgery, a patient substance cons before an exam, and R Ntgen-aspirated cardiac arrest and died. The median follow-up time